Singapore, Nov. 20 -- US-based Agilent Technologies Inc. has announced the launch of SureSelect Cancer Research Pan Heme, a hybrid capture-based next-generation sequencing (NGS) research solution for comprehensive genomic profiling of hematologic malignancies.

Developed in collaboration with experts at Roswell Park Comprehensive Cancer Center, the solution integrates DNA and RNA profiling, automated sample preparation and bioinformatics in a streamlined workflow.The introduction of SureSelect Cancer Research Pan Heme expands Agilent's tumour profiling portfolio for cancer research, providing a purpose-built solution for comprehensive profiling of hematologic tumors alongside SureSelect Cancer Research CGP for solid tumors and SureSelect ...